Targeted genome editing using the CRISPR-Cas9 system is easy to use but far from being perfect. Computer calculated modification of CRISPR activity can reduce "off-target effects".

Dutch biotech Azafaros B.V. has closed a €25m Series A financing round.

Infants who show defective immune responses to microbial components are more likely to acquire asthma later in childhood, according to a study of 541 children.

MaaT Pharma SA has announced €18m Series B financing to boost its microbiome biotherapeutics pipeline.

Ex-Sandoz Head of Global Franchises Rex Clements is taking over as CEO of Centrient Pharmaceuticals. Erstwhile Centrient CEO Karl Rotthier has decided to step down, the company said.

French vaccine developer Valneva SA will raise $85m in a financing arrangement with Deerfield and OrbiMed and go Nasdaq to co-fund its Lyme disease programme.

The EMA’s human medicines committee (CHMP) recommended fifteen medicines for approval at its January 2020 meeting.

European venture capital firm Sofinnova Partners announced the promotion of Michael Krel to Partner of the Industrial Biotechnology team. Krel previously served as Principal on the team, where he focused on early-stage deals in Europe and North America.

The 10th edition of the European Biotechnology Science & Industry Guide once more offers an interesting cross-section of the European biotech scene.

Researchers at the University of Luebeck have revealed the structure of the IMP dehydrogenase, a central target of T. brucei, which causes sleeping sickness.